Alimta
(Pemetrexed)ApprovedSmall molecule
Pemetrexed is used to treat certain types of cancer, including lung cancer and mesothelioma (a cancer caused by asbestos exposure). It works by stopping cancer cells from growing and dividing.[2] Alimta is currently approved and in use across 56 indications[4].[1]
Alimta is one of 1077 small molecule programs targeting Glioma. It is currently in Approved.
56
Indications
716
Total Trials
52
Active Trials
1,076
Competitors
7
FDA Applications
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 56 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Alimta
EEagle Vision Pharmaceutical Corp.
Approved
Trodelvy
GileadPreclinical
Zolymbus
AbbViePreclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer57 trials
Show 54 more trials
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression
Terminated·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT02919462·2 enrolled
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Terminated·—·Phase 1·NCT04173338·9 enrolled
Lung Cancer19 trials
Show 16 more trials
Small Cell Lung Cancer11 trials
Show 8 more trials
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
Completed·—·Phase 1/2·NCT00216203·36 enrolled
Chemotherapy6 trials
Non-squamous NSCLC5 trials
Show 2 more trials
Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00769600·23 enrolled
70 more indications
Malignant Pleural Mesothelioma5 trials
Advanced Solid Tumors5 trials
Colorectal Cancer3 trials
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04683965·27 enrolled
Advanced NSCLC3 trials
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT03987867·30 enrolled
Metastatic Solid Tumors3 trials
Lung Adenocarcinoma3 trials
Mesothelioma2 trials
Metastatic NSCLC2 trials
First Line Therapy2 trials
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy
Terminated·—·Phase 2·NCT00998166·12 enrolled
Esophageal Cancer2 trials
Leptomeningeal Metastasis2 trials
Cisplatin2 trials
Leptomeningeal Metastases2 trials
Pleural Mesothelioma2 trials
Pembrolizumab2 trials
Elderly Patients2 trials
Advanced Cancer2 trials
Breast Cancer2 trials
First-line2 trials
Plasma-Adapted First-Line Pembro In NSCLC
Active, not recruiting·—·Phase 2·NCT04166487·40 enrolled
Solid Tumors2 trials
Central Nervous System Lymphoma1 trial
Locally Advanced or Metastatic Solid Tumors1 trial
Induction Chemotherapy1 trial
Ovarian Cancer1 trial
Hypofractionated Radiotherapy1 trial
Adult Subject1 trial
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06917079·387 enrolled
Circulating Tumor Cell1 trial
Thoracic Tumors1 trial
Patients With Advanced Solid Tumors1 trial
Medulloblastoma1 trial
Glioma1 trial
Patients With Solid Tumors1 trial
Lymphoma1 trial
Metastatic Tumors1 trial
Adjuvant Treatment1 trial
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT04455594·168 enrolled
NSCLC Stage III1 trial
First-line Treatment1 trial
Stage IB-IIIA NSCLC1 trial
Small Cell Cancer1 trial
Chemoradiotherapy1 trial
Non-Small Cell Lung Carcinoma1 trial
Effectiveness1 trial
Efficacy and Safety1 trial
Prostate Cancer1 trial
Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Completed·—·Phase 2·NCT00216099·49 enrolled
Locally Advanced Head and Neck Cancer1 trial
Cytoreductive Surgery1 trial
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
Terminated·—·Phase 1·NCT02838745·7 enrolled
Metastatic Cancer1 trial
Advanced Cancers1 trial
Recurrent or Metastatic1 trial
Advanced Solid Tumor1 trial
Primary Peritoneal Carcinoma1 trial
Phase II1 trial
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT05870319·376 enrolled
Primary Peritoneal Cancer1 trial
Metastatic Colorectal Cancer1 trial
Bladder Cancer1 trial
Malignant Glioma1 trial
Advanced Solid Tumours1 trial
Regulatory
FDA Approval Timeline[5]
Sep 7, 2007
ALIMTA
NDA NDA021462
Feb 8, 2020
PEMFEXY
NDA NDA209472
Aug 21, 2020
PEMETREXED
NDA NDA208419
May 26, 2022
PEMETREXED DISODIUM
NDA NDA214657
Jun 22, 2022
PEMETREXED DISODIUM
NDA NDA214218
Jul 19, 2022
PEMETREXED DISODIUM
NDA NDA214408
May 22, 2023
PEMETREXED
NDA NDA215179
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Alimta drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Pemetrexed. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Alimta. U.S. Food & Drug Administration.
- [7]